This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2007 by HaEmek Medical Center, Israel.
Recruitment status was:  Recruiting
Information provided by:
HaEmek Medical Center, Israel Identifier:
First received: June 19, 2007
Last updated: June 20, 2007
Last verified: June 2007

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.

Condition Intervention
Kidney Stones Drug: tamsulosin 0.4mg

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: May 2007

Ages Eligible for Study:   15 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • size of stone 1-2 cm

Exclusion Criteria:

  • ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00489723

Contact: DORON PEREZ, M.D. +972-4-6495115

Haemek medical center Recruiting
Afula, Israel, 18100
Contact: DORON PEREZ, M.D.    +972-4-6495115   
Principal Investigator: doron perez, M.D.         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Principal Investigator: doron perez Urology department: Haemek Medical Center
  More Information Identifier: NCT00489723     History of Changes
Other Study ID Numbers: 0056-07-EMC
Study First Received: June 19, 2007
Last Updated: June 20, 2007

Keywords provided by HaEmek Medical Center, Israel:
size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:
Kidney Calculi
Kidney Diseases
Urologic Diseases
Urinary Calculi
Pathological Conditions, Anatomical
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on August 18, 2017